Witty targets suppliers in cost-cutting drive for GSK malaria vaccine
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline chief executive officer Andrew Witty, during a recent conference call reviewing pivotal Phase III interim data on the company's RTS,S candidate, said he will be asking suppliers for its malaria vaccine products to cut their costs and profits so that the vaccine can be made available as cheaply as possible.